Rhamnolipid-coated W/O/W double emulsion nanoparticles for efficient delivery of doxorubicin/erlotinib and combination chemotherapy

• DOI: 10.1186/s12951-021-01160-4
• Publication Date: 2021-12-07T10:02:42Z
• Authors: Yeeun Lee; Donghyun Lee; Eunyoung Park; Seok-young Jang; Seo Young Cheon; Seongryeong Han; Heebeom Koo
• Keywords: 0301 basic medicine; Cell Survival; Antineoplastic Agents; Erlotinib Hydrochloride; Mice; 03 medical and health sciences; Nanoparticle; Cell Line, Tumor; Medical technology; Animals; Combination therapy; R855-855.5; Research; Optical Imaging; Double emulsion; 3. Good health; Erlotinib; Rhamnolipid; Doxorubicin; Nanoparticles; Drug Therapy, Combination; Emulsions; Glycolipids; TP248.13-248.65; Biotechnology

Combination therapy using more than one drug can result in a synergetic effect clinical treatment of cancer. For this, it is important to develop an efficient delivery system that contain multiple drugs and provide high accumulation tumor tissue. In particular, simultaneous stable loading with different chemical properties into single nanoparticle carrier difficult problem.We developed rhamnolipid-coated double emulsion nanoparticles containing doxorubicin erlotinib (RL-NP-DOX-ERL) for tissue combination chemotherapy. The method enabled hydrophilic DOX hydrophobic ERL the NPs, biosurfactant RL provided surface coating. resulting NPs showed fast cellular uptake cell killing SCC7 cells. real-time imaging, they mice after intravenous injection. Furthermore, enhanced suppression was observed by RL-NP-DOX-ERL same mouse model compared control groups free drug.The successful effect. Importantly, this study demonstrated promising potential double-emulsion coating therapy.